The U.S. FDA has approved Merck's new cholesterol-lowering pill, Lipfendra. This oral medication works by blocking the PCSK9 protein, which helps lower bad cholesterol. Lipfendra offers an alternative for patients who dislike injectable treatments for heart disease. The drug is priced at $10.50 daily and will be available soon. Merck expects Lipfendra to significantly improve treatment for many high-risk patients.